Novo Nordisk A/S
NVO
$160.76
$2.911.84%
| 12/31/2022 | 09/30/2022 | 06/30/2022 | 03/31/2022 | 12/31/2021 | |
|---|---|---|---|---|---|
| Revenue | 6.61B | 6.17B | 5.91B | 6.34B | 5.89B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.61B | 6.17B | 5.91B | 6.34B | 5.89B |
| Cost of Revenue | 1.13B | 975.13M | 868.89M | 1.04B | 959.51M |
| Gross Profit | 5.47B | 5.20B | 5.04B | 5.30B | 4.93B |
| SG&A Expenses | 2.07B | 1.71B | 1.69B | 1.68B | 1.97B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -66.48M | -8.13M | -21.33M | -59.14M | -18.45M |
| Total Operating Expenses | 4.15B | 3.44B | 3.27B | 3.45B | 3.69B |
| Operating Income | 2.46B | 2.73B | 2.63B | 2.89B | 2.20B |
| Income Before Tax | 2.24B | 2.44B | 2.40B | 2.70B | 2.02B |
| Income Tax Expenses | 374.17M | 491.22M | 497.80M | 559.60M | 341.46M |
| Earnings from Continuing Operations | 1.87B | 1.95B | 1.91B | 2.14B | 1.67B |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.87B | 1.95B | 1.91B | 2.14B | 1.67B |
| EBIT | 2.46B | 2.73B | 2.63B | 2.89B | 2.20B |
| EBITDA | 2.64B | 3.01B | 2.87B | 3.14B | 2.24B |
| EPS Basic | 0.83 | 0.86 | 0.84 | 0.94 | 0.73 |
| Normalized Basic EPS | 0.67 | 0.67 | 0.66 | 0.74 | 0.57 |
| EPS Diluted | 0.83 | 0.86 | 0.84 | 0.94 | 0.73 |
| Normalized Diluted EPS | 0.67 | 0.67 | 0.66 | 0.74 | 0.57 |
| Average Basic Shares Outstanding | 2.25B | 2.26B | 2.27B | 2.28B | 2.28B |
| Average Diluted Shares Outstanding | 2.26B | 2.27B | 2.28B | 2.28B | 2.29B |
| Dividend Per Share | 1.12 | 0.00 | 0.61 | -- | 1.06 |
| Payout Ratio | 0.00% | 66.73% | 0.00% | 110.42% | 0.00% |
